Malignant Neoplasms Clinical Trials

4 recruiting

Malignant Neoplasms Trials at a Glance

13 actively recruiting trials for malignant neoplasms are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Houston, Guangzhou, and Bethesda. Lead sponsors running malignant neoplasms studies include M.D. Anderson Cancer Center, Icahn School of Medicine at Mount Sinai, and Degron Therapeutics Co..

Browse malignant neoplasms trials by phase

Treatments under study

About Malignant Neoplasms Clinical Trials

Looking for clinical trials for Malignant Neoplasms? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 1

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Malignant Neoplasms of Respiratory and Intrathoracic OrgansSquamous Cell Carcinoma of the Larynx
M.D. Anderson Cancer Center11 enrolled1 locationNCT03114462
Recruiting
Phase 2

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NeoplasmsClear Cell Renal Cell CarcinomaMalignant Neoplasms+1 more
Yonsei University78 enrolled1 locationNCT07469683
Recruiting
Phase 1

A Study of DEG6498 in Participants With Solid Tumors

Malignant Neoplasms
Degron Therapeutics Co.100 enrolled1 locationNCT07244835
Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Phase 2

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Malignant Neoplasms of Digestive Organs
LaNova Medicines Zhejiang Co., Ltd.276 enrolled1 locationNCT05934331
Recruiting
Not Applicable

Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors

Malignant Neoplasms of Brain
Peking Union Medical College Hospital50 enrolled1 locationNCT07023640
Recruiting

An International Study on Pediatric Patients With Rare Tumors.

MesotheliomaThyroid CarcinomaPleuropulmonary Blastoma+11 more
Azienda Ospedaliera di Padova6,250 enrolled1 locationNCT07072143
Recruiting
Phase 2

Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Rectal Malignant Neoplasms
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07026422
Recruiting

A Multi Center Study of Sexual Toxicities After Radiotherapy

Malignant Neoplasms
Icahn School of Medicine at Mount Sinai300 enrolled3 locationsNCT05394428
Recruiting

PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): Pharmacogenomics primary study and discovery program

Cancer and other malignant neoplasms
Peter MacCallum Cancer Centre1,470 enrolled8 locationsACTRN12624000079549
Recruiting
Phase 2

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland TumorsSalivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University15 enrolled1 locationNCT05000892
Recruiting

Optical Genome Mapping in Hematological Malignancies

MDSALLOther Hematologic Malignant Neoplasms
University Hospital, Brest200 enrolled4 locationsNCT05009537